Strontium ranelate treatment prevents bone loss induced by Diabetes mellitus in rats

SEDLINSKY, CLAUDIA; FERNANDEZ JM; MOLINUEVO MS; SCHURMAN, LEÓN; ANA M. CORTIZO; ANTONIO D. MCCARTHY

Congreso; The Endocrine Society´s ENDO 2013; 2013

Bone homeostasis can be affected by metabolic diseases such as Diabetes mellitus, the consequence could be an increased risk for low – stress fractures. Bone loss is usually treated with antiresorptive drugs such as biphosphonates, nevertheless there are other therapeutic options available like strontium ranelate. It has previously been demonstrated that strontium ranelate (SR) administration improves bone microarchitecture in osteoporotic patients. In vitro studies have demonstrated that SR has a dual role increasing osteoblastic activity and inhibiting osteoclasts. Recently, we have demonstrated that SR can prevent the deleterious actions of advanced glycation end products on osteoblasts in culture. In the present work we have evaluated the effect of SR administration on bone microarchitecture in diabetic rats, and on the osteogenic potential of bone marrow progenitor cells (BMPC) isolated from these animals. Diabetes was induced by the consecutive i.p. administration of streptozotocin and nicotinamide to 10 adult Sprague-Dowley rats. Diabetic animals were divided into two groups: diabetic (D, water ad libitum) and diabetic plus 625 mg/kg/day SR in drinking water (DR). For comparison, a group of non-diabetic rats without treatment (control, C) were also included. After 2 weeks animals were sacrificed and femora were isolated either for histology or BMPC preparation. After 21 days of culture in osteogenic conditions, BMPC from D animals showed less osteogenic potential than control cells as evaluated by type I collagen production (72±6 % of C, p